ANI Pharmaceuticals Inc. completed a series of share transactions with Ampersand 2020 Limited Partnership. On November 19, 2021, ANI issued and sold 25,000 Series A Convertible Preferred Shares to Ampersand in a private placement at $1,000 per share, totaling $25 million. Subsequently, Ampersand converted 5,000 Preferred Shares into 120,580 Common Shares on August 14, 2025, and the remaining 20,000 Preferred Shares were mandatorily converted into 482,320 Common Shares on September 26, 2025. In total, all 25,000 Preferred Shares were converted into 602,900 Common Shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001023024-25-000099), on September 26, 2025, and is solely responsible for the information contained therein.